Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug305 | Anti-SARS-CoV-2 Human Convalescent Plasma Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
| D018352 | Coronavirus Infections NIH | 0.04 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
The question of the immune response of the population, particularly of professional populations in contact with vulnerable populations (such as those with chronic conditions such as cancer), is an important issue. Knowing the evolution of this response over time in this population can help answer outstanding questions. The PRO-SERO-COV study is a seroprevalence study of caregivers working in the hospital sector with a follow-up at 3 months and 12 months. The objective is to evaluate and monitor at 3 and 12 months the serological immune status to an infection by the SARS-CoV-2 virus in active volunteer professionals working at the Institut Bergonié with different types of exposure: healthcare professionals and professionals in other services.
Description: This will be determined from the detection of specific antibodies (immunoglobulins: IgM and IgG) or total antibodies carried out using the ELISA/ECLIA method allowing qualitative and semi-quantitative measures. These ELISA/ECLIA tests will be carried out in the medical biology laboratory of the Institut Bergonié.
Measure: Serological immune status to an infection by the SARS-CoV-2 virus Time: Time 0 (Inclusion)Description: This will be determined from the detection of specific antibodies (immunoglobulins: IgM and IgG) or total antibodies carried out using the ELISA/ECLIA method allowing qualitative and semi-quantitative measures. These ELISA/ECLIA tests will be carried out in the medical biology laboratory of the Institut Bergonié.
Measure: Serological immune status to an infection by the SARS-CoV-2 virus Time: 3 months, 12 monthsDescription: This will be determined from the detection of specific antibodies (immunoglobulins: IgA) carried out using the ELISA/ECLIA method allowing qualitative and semi-quantitative measures. These ELISA/ECLIA tests will be carried out in the medical biology laboratory of the Institut Bergonié.
Measure: Serological immune status to an infection by the SARS-CoV-2 virus Time: Time 0 (inclusion), 3 months, 12 monthsDescription: Assessment using a " rapid test on cassette ".
Measure: The serological immune status to infection with the SARS-CoV-2 virus will also be determined from the different antibody isotypes (IgG and IgM), from a rapid diagnostic unit test (RDT). Time: Time 0 (inclusion), 3 months, 12 monthsDescription: Defined by a positive result for the molecular test for the detection of the SARS-CoV-2 coronavirus genome by RT-PCR.
Measure: active COVID-19 infection Time: Time 0 (inclusion), 3 months, 12 monthsDescription: GAD-7 self-questionnaire (Spitzer et al. 2006), whose score varies from 0 to 21. The recommended threshold for estimating generalized anxiety is 10 points
Measure: symptoms of anxiety Time: Time 0 (inclusion), 3 months, 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports